« Return to News | CROs/Service Providers

Novotech attracts investment for Asian clinical trial expansion

Monday, May 6, 2013 11:08 AM

Novotech, an Australia-based independent CRO, received a funding injection from private equity firm Mercury Capital.

"Novotech is focused on the fast-growing Asia region,” said Alek Safarian, CEO of Novotech. “We are already active in 10 countries in the region on behalf of our biotechnology and pharmaceutical clients. This investment will further accelerate our expansion plans." 

Mercury Capital, founded by former Goldman Sachs managing director Clark Perkins, acquired a 30% stake in Novotech and has the option to increase this to 50% at a later date.

"We're excited by the organic growth opportunities in Australia and Asia, and acquisition opportunities in the latter," Perkins told The Wall Street Journal in a recent interview. “There's a strong trend of major pharmaceutical companies outsourcing, which has led to underlying annual compound growth in the market of between 5% and 10%. Novotech is growing much faster than this.”

Novotech works currently manages around 70 trials across a wide range of therapeutic areas including oncology and cardiovascular disease. Novotech has offices in Australia, New Zealand, Singapore, India, Malaysia, Thailand, Taiwan and South Korea, has been instrumental in the success of hundreds of phase I-IV clinical trials.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.